» Articles » PMID: 24583030

A Murine Model of Coxsackievirus A16 Infection for Anti-viral Evaluation

Overview
Journal Antiviral Res
Publisher Elsevier
Date 2014 Mar 4
PMID 24583030
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

Coxsackievirus A16 (CA16) is one of the main causative agents of hand, foot and mouth disease (HFMD), which is a common infectious disease in children. CA16 infection may lead to severe nervous system damage and even death in humans. However, study of the pathogenesis of CA16 infection and development of vaccines and anti-viral agents are hindered partly by the lack of an appropriate small animal model. In the present study, we developed and characterized a murine model of CA16 infection. We show that neonatal mice are susceptible to CA16 infection via intraperitoneal inoculation. One-day-old mice infected with 2×10(6)TCID50 of CA16/SZ05 strain consistently exhibited clinical signs, including reduced mobility, and limb weakness and paralysis. About 57% of the mice died within 14days after infection. Significant damage in the brainstem, limb muscles and intestines of the infected mice in the moribund state was observed by histological examination, and the presence of CA16 in neurons of the brainstem was demonstrated by immunohistochemical staining with a CA16-specific polyclonal antibody, strongly suggesting the involvement of the central nervous system in CA16 infection. Analysis of virus titers in various organs/tissues collected at 3, 6 and 9days post-infection, showed that skeletal muscle was the major site of virus replication at the early stage of infection, while the virus mainly accumulated in the brain at the late stage. In addition, susceptibility of mice to CA16 infection was found to be age dependent. Moreover, different CA16 strains could exhibit varied virulence in vivo. Importantly, we demonstrated that post-exposure treatment with an anti-CA16 monoclonal antibody fully protected mice against lethal CA16 infection. Collectively, these results indicate the successful development of a CA16 infection mouse model for anti-viral evaluation.

Citing Articles

Neutralizing antibody landscape of the non-polio Enteroviruses and future strategy.

Wang H, Zhu W, Li Y, Sun M Front Immunol. 2025; 15:1524356.

PMID: 39877351 PMC: 11772190. DOI: 10.3389/fimmu.2024.1524356.


Hand, Foot, and Mouth Disease (HFMD) in India: A Review on Clinical Manifestations, Molecular Epidemiology, Pathogenesis, and Prevention.

Tikute S, Lavania M Indian Dermatol Online J. 2023; 14(4):475-481.

PMID: 37521225 PMC: 10373810. DOI: 10.4103/idoj.idoj_423_22.


The development and characterization of a stable Coxsackievirus A16 infectious clone with Nanoluc reporter gene.

Yu R, Wang M, Liu L, Yan J, Fan J, Li X Front Microbiol. 2023; 13:1101850.

PMID: 36704559 PMC: 9871592. DOI: 10.3389/fmicb.2022.1101850.


Non-neutralizing monoclonal antibody targeting VP2 EF loop of Coxsackievirus A16 can protect mice from lethal attack via Fc-dependent effector mechanism.

Du R, An C, Yao X, Wang Y, Wang G, Gao F Emerg Microbes Infect. 2022; 12(1):2149352.

PMID: 36395069 PMC: 9788719. DOI: 10.1080/22221751.2022.2149352.


Optimization of Vero Cells Grown on a Polymer Fiber Carrier in a Disposable Bioreactor for Inactivated Coxsackievirus A16 Vaccine Development.

Chen K, Li C, Wang Y, Shen Z, Guo Y, Li X Vaccines (Basel). 2021; 9(6).

PMID: 34200441 PMC: 8229131. DOI: 10.3390/vaccines9060613.